Next-Generation Hybrid Adenoviral Vectors for Personalized Vaccine Development

The present inventive concept envisions a paradigm shift in adenoviral vector-based vaccine development by leveraging machine learning, cloud-based platforms, and CRISPR-Cas9 genome editing to create personalized, rapidly developed, and highly immunogenic vaccines.

The original patent relates to novel adenoviral vectors derived from chimpanzee adenovirus, but it has limitations in terms of vector design, immunogenicity, and manufacturing. The present inventive concept addresses these limitations by introducing machine learning algorithms to optimize vector design, cloud-based platforms for rapid development, and CRISPR-Cas9 genome editing for in vivo vector evolution.

The inventive concept comprises a system for generating hybrid adenoviral vectors using machine learning algorithms to optimize vector design and immunogenicity. This system includes a database of adenoviral sequences, a machine learning module, and a vector design module. Additionally, the concept encompasses a method for rapid development of adenoviral vector-based vaccines using a cloud-based platform, comprising a user interface for inputting target antigen sequences, a vector design module, and a manufacturing module for producing the designed vectors. Furthermore, the concept includes a hybrid adenoviral vector comprising a capsid from a chimpanzee adenovirus and a genetic payload from a human adenovirus, designed to elicit a broad immune response against multiple antigens. The concept also encompasses a system for personalized adenoviral vector-based vaccine development, comprising a patient data module, a machine learning module, and a vector design module, generating a customized vector based on the patient's genetic profile and immune status. Finally, the concept includes a method for in vivo vector evolution using CRISPR-Cas9 genome editing, comprising a vector design module, a genome editing module, and a selection module for identifying evolved vectors with improved immunogenicity.

The new claims introduce the use of machine learning algorithms, cloud-based platforms, and CRISPR-Cas9 genome editing, which are not present in the original patent. These novel elements provide a significant inventive step, enabling rapid, personalized, and highly immunogenic vaccine development.

Alternative embodiments of the inventive concept could include the use of different machine learning algorithms, various cloud-based platforms, or alternative genome editing techniques. Additionally, the concept could be adapted for use in different disease areas or for developing vaccines against emerging pathogens.

The inventive concept has significant commercial potential in the vaccine development market, particularly in the areas of personalized medicine, infectious disease prevention, and pandemic response. The concept could be licensed to biotech and pharmaceutical companies, or used to establish a new company focused on rapid vaccine development.